200 results about "Cervical cancer" patented technology

The invention relates to the field of natural products, in particular to a dimer compound of guaiane type sesquiterpenes and uric acid as well as an extraction and separation method and application of the dimer compound. According to the invention, a new dimer compound of guaiane type sesquiterpene and uric acid is extracted and separated from carpesium abrotanoides in Guizhou, and it is found that the dimer compound has relatively strong anti-tumor activity. The compound has strong inhibitory activity on breast cancer, prostate cancer, nasopharynx cancer, liver cancer, lung cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, skin cancer, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer, and provides an optional scheme for broad-spectrum anti-cancer drugs. Moreover, in human prostate cancer cells PC3, human cervical cancer cells Hela, human liver cancer cells HepG2 and human glioma cells U87 which are resistant to paclitaxel, the compound also shows strong anti-cancer activity, which indicates that the compound has the potential of treating patients resistant to paclitaxel.

This invention relates to the field of anticancer drugs, and more particularly to an indole-3-aryl ketone derivative, its preparation method, and its applications. The indole-3-aryl ketone derivative is compound I-VI, which can be used to prepare drugs for the prevention and / or treatment of cancer, including at least one of breast cancer, liver cancer, lung cancer, colorectal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, cervical cancer, ovarian cancer, kidney cancer, and esophageal cancer. This invention screened the activity of various compounds and, for the first time, discovered that compound I-VI exhibits excellent inhibitory activity against multiple different types of human cancer cells, providing a potential option for broad-spectrum anticancer drugs.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses a cyclophosphamide ternary nano-micelle and a preparation method thereof.The cyclophosphamide ternary nano-micelle prepared through the method can be used for treating malignant lymphoma, multiple myeloma, leukemia, breast cancer, ovarian cancer, cervical cancer, prostatic cancer, colon cancer, bronchial cancer, lung cancer and the like. Reasonable preparation steps and a preparation formula are adopted, the use of an organic reagent is reduced, the irritation of cyclophosphamide is reduced and the stability of the micelle is improved by adjusting a freeze-drying technology, and the cyclophosphamide micelle adopts amphiphilic macromolecules as a carrier material, so that the drug loading capacity and the stability of the micelle are obviously improved, and the bioavailability of the micelle is improved. The ternary nano-micelle system has the advantages that the solubility of cyclophosphamide is improved, the in-vivo bioavailability is increased, the preparation method is simple, the micelle performance is stable, and large-scale industrial production is facilitated.

The present invention relates to a hetero (aromatic) ring-substituted cyclic diamine compound, the preparation thereof and the use thereof in the preparation of a drug for treating and / or preventing tumors. The structural formula of the compound is as shown in (I). The compound has a significant inhibitory effect on the growth of cells of tumors such as leukemia, lymphoma, breast cancer, melanoma, ovarian cancer, colorectal cancer, cervical cancer, lung cancer, prostate cancer, esophageal cancer, glioma, kidney cancer, nasopharyngeal carcinoma, liver cancer, gastric cancer and pancreatic cancer. Compared with the prior art, the compound of the present invention has a broad-spectrum anti-tumor activity, has a good effect on inhibiting tumors, and has an effect of degrading PD-L1 proteins, and is thus a PD-L1 immunomodulator.

The invention discloses a limonin compound and application thereof in preparation of a medicine for preventing and / or treating cancers. The structure of the limonin compound is shown as a formula I or II. The cancer is at least one of breast cancer, liver cancer, gastric cancer, esophageal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, prostatic cancer, nasopharynx cancer, cervical cancer, ovarian cancer, kidney cancer and skin cancer. According to the invention, activity screening is carried out on various natural product extracts, it is found for the first time that limonin compounds with structural formulas I and II have excellent inhibitory activity on various different types of human cancer cells, and an optional scheme is provided for broad-spectrum anti-cancer drugs. Related results also show that the compound provided by the invention can inhibit migration and invasion ability of breast cancer cells, promote cell apoptosis and retard a cell cycle. The limonin compound applied in the invention is derived from mallotus oblongifolius, the source is wide, and the production cost is low.

The invention relates to the field of anti-cancer drugs, in particular to an indole-3-aryl ketone derivative as well as a preparation method and application thereof. The indole-3-aryl ketone derivative is a compound I-VI, the indole-3-aryl ketone derivative can be used for preparing drugs for preventing and / or treating cancers, and the cancers comprise at least one of breast cancer, liver cancer, lung cancer, colorectal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer. According to the invention, activity screening is carried out on various compounds, the fact that the compounds I-VI have excellent inhibitory activity on various different types of human cancer cells is found for the first time, and an optional scheme is provided for broad-spectrum anti-cancer drugs.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a 3-sulfamoyl benzamide compound as well as a preparation method and application thereof. The 3-sulfamoyl benzamide compound has a structure as shown in a formula I. In the formula I, X is chlorine or trifluoromethyl; r1 and R2 are independently C1-4 alkyl or R1, R2 and N atoms connected with R1 and R2 jointly form a heterocyclic group, and the heterocyclic group is a substituted or unsubstituted five-membered or six-membered heterocyclic group; and when the heterocyclic group is a substituted heterocyclic group, the substituent group in the substituted heterocyclic group is one or more of C1-4 alkyl, phenyl and acetyl. The 3-sulfamoyl benzamide compound disclosed by the invention has a remarkable proliferation inhibition effect on HCT116 colon cancer cells, HeLa human cervical cancer cells, MDA-MB-231 human breast cancer cells and A375 human malignant melanoma cells.

The invention belongs to the technical field of biomedical functional dyes and probes, and relates to a fluorescent probe, in particular to a cyclodextrin-based near-infrared fluorescent probe, which is a conjugate formed by coating a fluorescent molecule with cyclodextrin. According to the near-infrared fluorescent probe disclosed by the invention, cyclodextrin is nested on a carbon chain of a fluorescent molecule, so that the water solubility, histocompatibility and safety are improved, the fluorescence lifetime is prolonged, the light stability is improved, and rapid transmission and response of ureters, lymphatic vessels and lymph nodes in vivo are realized; the method can be used for NIR-I and NIR-II imaging; a near-infrared fluorescence probe with targeting property can be formed by marking various tumor targeting molecules, so that accurate targeting fluorescence imaging of different types of tumors such as urogenital tumors, head and neck cancers, breast cancers and cervical cancers and metastatic lymph nodes in NIR-I and NIR-II windows is realized, and the near-infrared fluorescence probe can be applied to fluorescence imaging navigation in clinical operations.

The invention relates to a hetero (aromatic) ring substituted cyclic diamine compound, preparation thereof and application of the hetero (aromatic) ring substituted cyclic diamine compound in preparation of drugs for treating and / or preventing tumors. The structural formula of the compound is shown as (I). The compound has an obvious growth inhibition effect on tumor cells of leukemia, lymphoma, breast cancer, melanoma, ovarian cancer, colorectal cancer, cervical cancer, lung cancer, prostate cancer, esophagus cancer, glioma, kidney cancer, nasopharynx cancer, liver cancer, stomach cancer, pancreatic cancer and the like. The compound disclosed by the invention has broad-spectrum anti-tumor activity; the compound has a good tumor inhibition effect and a PD-L1 protein degradation effect, and is a PD-L1 immunomodulator.

The invention relates to a 5, 9-di-tert-butyl naphtho-indolizine phenothiazine compound as well as a preparation method and medical application thereof. The compound is efficiently synthesized through Ullmann coupling and palladium-catalyzed intramolecular arylation reaction. In-vitro anti-tumor activity research shows that the compound has remarkable selective inhibitory activity on various human tumor cell lines, and particularly, the inhibitory effect on non-small cell lung cancer A549 cells (IC50 = 0.21 mu M) is improved by two orders of magnitude compared with that of cis-platinum; iC50 (half maximal inhibitory concentration) of other cell lines are as follows: 1.26 mu M of prostate cancer PC-3 cells, 6.78 mu M of liver cancer HepG2 cells, 7.99 mu M of cervical cancer Hela cells and 25.46 mu M of breast cancer MCF-7 cells. Preliminary toxicity experiments prove that the compound has the characteristic of low cytotoxicity. The compound can be used as a novel high-efficiency low-toxicity anti-tumor lead compound, and provides an important structural basis for the development of anti-cancer drugs.

The invention discloses a specific metabolic marker combination for diagnosing ovarian cancer and application thereof, and belongs to the field of markers for detecting ovarian cancer. The invention discloses a specific metabolic marker combination for diagnosing ovarian cancer. The specific metabolic marker combination comprises phosphatidylcholine 36: 6, sphingomyelin d40: 2 and sphingomyelin d41: 2. According to the invention, a metabonomics technology is used to screen out a specific metabolism marker combination for diagnosing ovarian cancer, and the specific metabolism marker combination has high sensitivity in ovarian cancer diagnosis and has high diagnosis capability for ovarian cancer diagnosis. The specific metabolic marker combination also has high specificity in ovarian cancer diagnosis, but is not applicable to diagnosis of endometrial cancer and cervical cancer. In addition, the plasma sample acquisition mode has the advantages of non-invasiveness and convenience, and has a wide application prospect in the research of biomarkers.

The present disclosure features methods for identifying pateints having a hyperproliferative disease, disorder, or condition responsive to phosphodiesterase 3 (PDE3) and schlafen family member 12 (SLFN12) complex formation. The hyperproliferative disease, disorder, or condition may be cancer in a patient including glioblastoma, melanoma, ovarian cancer, cervical cancer, sarcoma, or hematopoietic cancers, such as acute myeloid leukemia. Those responsive diseases, disorders, or conditions may be identified using the biomarker AIP and / or TRRAP in combination with those biomarkers pertinent to phosphodieseterase 3 and schlafen family member 12 complexes which may be formed by PDE3 modulation with certain active compounds. Expression of combinations of these biomarkers have been shown to correlate with active compound (e.g., PDE3 modulator, PDE3A modulator, PDE3B modulator) sensitivity.

The present invention relates to a biological sample self-collection device that houses a collector (such as a “veil”, buffer, swab, brush, etc.) for any biological material, preferably of vaginal origin. At the same time, it is designed to combine a reactive liquid with said substances for subsequent analysis thereof in a watertight manner. Its use includes the detection of pathogens, such as human papillomavirus, and the diagnosis of cervical cancer, among others.

The present application relates to a kind of five-ring thiazole indole ketone piperazine amide derivatives and purposes thereof.The derivatives take ethyl cyanoacetate as starting material, generate hydroxylamine compound (A) under the action of sodium nitrite and phosphoric acid;Obtain 2-amino ethyl cyanoacetate (B) by reduction, in turn with acetic anhydride, lawson reagent is reacted, and 5-amino-4-carboxylate thiazole compound (D) is obtained;After bromination by NBS, under the catalysis of phosphorus oxychloride, react with tetrahydropyridine indole ketone, generate 2-bromo-6,7-dihydrothiazolo [5'',4'':4',5'] pyrimido [1',2':1,2] pyrindo [3,4-b] indole-4 (12H) -ketone (F), again under alkaline condition, first with Boc piperazine, then by Boc treatment and obtain compound (H);Finally, react with acyl chloride, and 28 different substitution structures of five-ring thiazole indole ketone piperazine amide compound (I1-I28) are synthesized.The 28 compounds are tested on three kinds of cancer cells, and the results show that: 28 compounds have significant inhibitory activity on Hela cervical cancer cells, HT-29 human colon cancer cells and HGC-27 human gastric cancer cells.

The invention belongs to the field of organic synthesis and medicinal chemistry, and particularly provides an efficient synthesis method of an N, N-diphenyl aniline compound based on a naphtho-indolizino-phenothiazine skeleton and anti-tumor application of the N, N-diphenyl aniline compound based on the naphtho-indolizino-phenothiazine skeleton. Through Suzuki reaction, functional coupling based on a naphtho-indolizino-phenothiazine skeleton and an N, N-diphenyl aniline group is realized for the first time. In-vitro anti-tumor evaluation shows that the compound has remarkable inhibitory activity on various human tumor cells, especially has the strongest effect on breast cancer MCF-7 cells (IC50 = 0.15 mu M), and the activity is improved by 266 times compared with that of cis-platinum; prostate cancer PC-3, liver cancer HepG2, lung adenocarcinoma A549 and cervical cancer Hela cells are also remarkably inhibited. The toxicity to normal umbilical vein endothelial cells (HUVEC) is far lower than that of tumor cells, and the selectivity is excellent. The research provides a lead compound with great potential for developing high-efficiency and low-toxicity targeted anti-tumor drugs.

The application discloses application of a naphthalene nitrile derivative in preparation of an antitumor pharmaceutical composition, in particular, application of a 2-(imino)-naphthalene nitrile derivative in preparation of an antitumor pharmaceutical composition. The 2-(imino)-naphthalene nitrile derivative provided by the application has a significant inhibiting effect on colon cancer, liver cancer, lung cancer, prostate cancer, cervical cancer, neuroglioma and breast cancer, exhibits excellent antitumor characteristics, can be used as a leading drug molecule for resisting tumors, and has a good development and application prospect in development of antitumor drugs.

The invention discloses a preparation method and application of a tridentate metal iridium complex, the preparation method of the tridentate metal iridium complex comprises the following steps: step 1, substituted 1, 3-benzene diformate and 2-aminothiophenol are subjected to cyclization reaction to obtain a first intermediate; 2, reacting iridium trichloride hydrate with the first intermediate obtained in the step 1 to obtain a second intermediate; and step 3, reacting an LX ligand with the second intermediate obtained in the step 2, and then using silver trifluoromethanesulfonate to obtain a target product. The tridentate clamp type metal iridium complex disclosed by the invention is composed of a substituted-1, 3-bis (benzothiazolyl) benzene main ligand, a 2, 2-dipyridyl or phenanthroline NN ligand and balanced chloride ions. The complex is simple in synthesis method and has high cytotoxicity to cervical cancer cells, colon cancer cells and lung cancer cells, and the in-vitro cell toxicity of the complex is obviously superior to that of clinically applied anti-tumor drug cis-platinum, so that the complex has a good application prospect in the field of metal anti-cancer drugs.

The invention provides a 1, 3, 4-oxadiazino tetrahydroisoquinoline compound as well as a preparation method and application thereof, and belongs to the technical field of heterocyclic compounds for medicines. The method comprises the following steps: by taking an azomethine imine substrate and a styrene oxide substrate as raw materials and cobalt perchlorate hexahydrate as a catalyst, adding the raw materials and the catalyst into a reaction solvent, reacting overnight at normal temperature, and performing column separation to obtain the 1, 3, 4-oxadiazino tetrahydroisoquinoline compound. According to the application, the reaction condition is mild, the selectivity is high, excellent cytotoxicity is shown on HeLa cervical cancer cells and A549 lung cancer cells, the half death inhibition ratio (IC50) value on tumor cells reaches the nanomole level, and the application has a good anti-cancer drug application prospect.

The invention provides a three-specificity immune cell adapter-cytokine fusion protein for malignant tumor immunotherapy as well as a preparation method and application of the three-specificity immune cell adapter-cytokine fusion protein. The fusion protein comprises a first binding domain, a second binding domain and a cytokine structural domain which are covalently linked to form a single polypeptide chain or polypeptide compound. The first binding domain is specifically bound with a tumor associated antigen, and the target spot of the first binding domain comprises but is not limited to KK-LC-1, MSLN, HER2, Claudin18.2, Claudin6 and PSMA; the second binding domain is specifically bound with a CD3 protein complex on the surface of the T cell; the cytokine domain is IL2, IL15, IL12, IL21 or a functional variant thereof. The invention also relates to a nucleic acid molecule for coding the fusion protein, an expression vector and application thereof. The fusion protein can be used for immunotherapy of malignant tumors such as colon cancer, gastric cancer, breast cancer, liver cancer, lung cancer and cervical cancer, and has a good application prospect. The invention effectively solves the problems of insufficient T cell activation and limited killing in solid tumor immunotherapy in the prior art.

The invention provides a 1-methyl-6-oxyindole-2-formamide derivative as well as a preparation method and application thereof, and belongs to the field of drug synthesis, the structural formula of the 1-methyl-6-oxyindole-2-formamide derivative is shown as a general formula I: # imgabs0, R1 is selected from # imgabs1, # imgabs2, # imgabs3, G = C or N, R2 is selected from a group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 8, 9, 10, 12, 13, 14, 16, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17 W = C or N. The 1-methyl-6-oxoindole-2-formamide mother nucleus group with biological activity contained in the compound is further chemically modified to generate a plurality of compounds with higher biological activity, so that the wide application of the compounds in biological medicines and the development prospect of pharmaceutical preparations are expanded. The compound can significantly inhibit proliferation of breast cancer, liver cancer, pancreatic cancer, gastric cancer, lung cancer, esophageal cancer, cervical cancer, multiple myeloma, diffuse large B-cell lymphoma and other cells at a low dosage (nanomole), and can effectively inhibit STAT3 protein phosphorylation, which shows that the compound has a prospect of being developed into antitumor drugs.

The present application relates to the field of polymer chemistry and biomedical technology, and particularly relates to a macrocyclic lactone polymer shown in formula (I) which is used for preventing or treating hyperproliferative diseases, including liver cancer, leukemia, breast cancer, colon adenocarcinoma, gastric cancer, lung cancer, Barrett's esophageal cancer, cervical cancer, pancreatic cancer, endometrial cancer, bone cancer, lymphoma, kidney cancer, brain cancer, nerve cancer, nasopharyngeal cancer, oral cancer, bladder cancer, colorectal cancer and melanoma, and has the potential to be developed into a new type of antitumor drug.

The application discloses a baicalin ternary co-amorphous drug and a preparation method and application thereof, and the amorphous substance can effectively improve the solubility and dissolution of puerarin and baicalin. The application mixes metformin hydrochloride, puerarin and baicalin according to a molar ratio of 1:1:1, and obtains the baicalin ternary co-amorphous drug through a ball milling method or a solvent-assisted milling method, the preparation method is green and efficient, the co-amorphous substance has high light stability and thermal stability, the solubility is increased by 1.7 times compared with that of a puerarin raw drug crystal, the solubility is increased by 46.8 times compared with that of a baicalin raw drug crystal, and the solubility is reduced by 14.8 times compared with that of a metformin hydrochloride raw drug crystal. The baicalin ternary co-amorphous drug has certain application prospects in liver protection, blood sugar reduction, treatment of damp-heat type colitis and cervical cancer.

The present disclosure is concerned with compounds and compositions for use in the prevention and treatment of cancer associated with FBOX21 mediated p85a ubiquitination such as, for example, cancer (e.g., sarcoma, a carcinoma, a hematological cancer, a solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanoma, a glioma, leukemia, lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, non-small cell lung carcinoma, renal cancer, lung cancer, colon cancer, cervical cancer, and plasma cell neoplasm (myeloma)). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The present disclosure is concerned with compounds and compositions for use in the prevention and treatment of cancer such as, for example, a primary or secondary tumor within a subject's brain, breast, kidney, pancreas, lung, colon, prostate, lymphatic system, liver, ovary, or cervix. Additional examples of cancers for which the disclosed compounds and compositions can be useful include, but are not limited to, sarcomas, carcinomas, hematological cancers, solid tumors, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanomas, gliomas, leukemia, lymphoma, chronic myeloproliferative disorders, myelodysplastic syndrome, myeloproliferative neoplasm, non-small cell lung carcinomas, and plasma cell neoplasms (myelomas). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

This invention discloses a lipid nanoparticle co-delivery system based on phenolic hydroxyl lipids and a manganese adjuvant. Addressing the shortcomings of traditional HPV therapeutic peptide vaccines—weak immunogenicity, easy degradation and inactivation in vivo, low bioavailability of manganese ion adjuvants making spatiotemporal co-delivery with antigens, and poor encapsulation efficiency and insufficient biosafety of conventional lipid nanocarriers—this invention constructs an integrated nanovaccine delivery system by embedding phenolic hydroxyl functional lipids into a nanocarrier framework, synergistically loading HPV E6 / E7 specific antigen peptides and manganese ion immune adjuvants. This system achieves efficient delivery, immune activation, and anti-tumor efficacy, integrating the functions of efficient antigen delivery, potent immune activation, and precise anti-tumor action. The preparation process is simple and exhibits excellent stability, overcoming the limitations of traditional HPV peptide vaccines with poor efficacy when used alone. It has broad research value and clinical translation prospects in the field of precision immunotherapy for HPV-related cervical cancer, head and neck squamous cell carcinoma, and other malignant tumors.

The invention relates to a sesquiterpenoid glycoside compound in Atractylodes lancea, and a preparation method and application thereof. The invention belongs to the technical field of medicines, and relates to a method for extracting and separating a sesquiterpenoid glycoside compound (1S, 5S, 7R, 10S)-10-hydroxy-deoxy split-ring atractylodes macrocephala delta-lactone-11-O-beta-D-glucopyranoside from rhizome of Atractylodes lancea by using normal phase silica gel, reverse phase silica gel, preparative high performance liquid chromatography and other technologies. In-vitro anti-tumor activity screening experiments show that the compound has good anti-tumor activity, including obvious inhibition effects on human lung cancer cells A549, human cervical cancer cells Hela and human liver cancer cells HepG-2. Therefore, the sesquiterpenoid glycoside compound has a prospect of being developed into antitumor drugs.

The ester derivatives of brefeldin A represented by Formula (I) in the inhibition of tumor proliferation. The compounds are prominent in the prevention or treatment of hyperproliferative diseases, including liver cancer, leukemia, breast cancer, colon adenocarcinoma, gastric cancer, lung cancer, Bart's esophageal cancer, cervical cancer, pancreatic cancer, endometrial cancer, bone cancer, lymphoma, kidney cancer, brain cancer, nerve cancer, nasopharyngeal cancer, oral cancer and colorectal cancer, and have the potential to be developed as antitumor agents.

The present invention discloses coumarin-3-carboxamide derivatives, their preparation methods, and their use in the preparation of anti-tumor drugs. The coumarin-3-carboxamide derivatives or pharmaceutically acceptable salts thereof have the structural formula shown in Formula (I): wherein R1 is hydrogen, an alkoxy group, or an amine group; R2 is hydrogen or a halogen atom; and m and n are 0 to 5. This invention is based on the development potential and value of coumarin derivatives in tumor treatment. The inventors of the present invention have studied coumarin-based anti-tumor drugs and discovered a series of coumarin derivatives with outstanding anti-tumor activity that can be used to treat breast cancer, oral cancer, or cervical cancer. #imgabs0#

The embodiment of the invention belongs to the technical field of medical image processing, and relates to a cervical cancer image report automatic generation method and related equipment, and the method comprises the steps: receiving a report generation request which is sent by a user terminal and carries a multi-sequence medical image; inputting the multi-sequence medical images into a multi-sequence three-dimensional MRI feature coding module for feature extraction operation to obtain medical image feature data; inputting the medical image feature data into a Mamb-Transform hybrid multi-mode decoding module to carry out an image report generation operation so as to obtain a medical image report; and outputting the medical image report to the user terminal. According to the method, the limitation of a traditional 2D image or a single-sequence 3D image is broken through, the unstructured, explainable and clinical-value image report is automatically generated on the basis of the three-dimensional multi-sequence MR I for the first time, and the method has wide clinical application value and important social benefits.

The present application relates to the technical field of in-vitro diagnosis, and in particular to a cell detection kit for the abnormality of human chromosomes 3 and 10 and a use thereof. A probe set comprised in the kit uses a specific chromosome locus or a centromere as a target, or uses a combination of a plurality of specific chromosome loci or centromeres as a target, so that the kit can rapidly and effectively detect a variety of cancer samples comprising lung cancer, breast cancer, intestinal cancer, esophageal cancer, bladder cancer, liver cancer, gastric cancer, pancreatic cancer, ovarian cancer, cervical cancer or prostate cancer, and is suitable for cancer diagnosis and development and popularization of prognostic products.